Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity

By afschroeder • September 25, 2025

Le X, Robichaux JP, Nilsson M, Vijayan RSK, Ravichandran A, Wu J, Elamin YY, Hong L, Pei J, He J, Patel S, Udagawa H, Mani S, Jang CW, Clarke JM, Tchekmedyian N, Goldman JW, Socinski M, Bhat G, Leu S, Bunn V, Su Z, Vincent S, Lawson JW, Cross JB, Heymach JV. Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity. Nat Commun. 2025 Sep 24;16(1):8358. doi: 10.1038/s41467-025-61817-8. PMID: 40993146.

Tags: Hematology/Oncology, Publications

Screening for frailty and malnutrition in a multidisciplinary head and neck cancer program

Brauer ER, Lazaro S, Economou DR, Rapkin D, Wong DJ, St John MA. Screening for frailty and malnutrition in a multidisciplinary head and neck cancer[...]

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

Nikitas J, Smith CP, Armstrong WR, Murthy V, Grogan T, Clark K, Moore J, Roberts M, Farolfi A, Reiter RE, Rettig MB, Shen J, Valle[...]

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen[...]